Company: IMNN
Filing Date: 2025-03-19
Form Type: DRS
Source: 0001641172-25-000007
Chunk: 13

Company: Imunon, Inc.
Filing Date: 2025-03-19
Form: DRS
Chunk 13
---
 
 before deciding to invest in our securities.                                                                                         |

The number of shares of our Common Stock outstanding is based on an aggregate of 14,620,754shares of our Common Stock outstanding as of March 18, 2025 and excludes:

| ● | 1,942,351                                                                                                                      
 shares of Common Stock issuable upon the exercise of outstanding stock options as of March 18, 2025, having a weighted average 
 exercise price of $1.79 per share;                                                                                             |
| ● | 39,700                                                                                                                         
 shares of Common Stock issuable upon the vesting of Common Stock awards as of March 18, 2025, having a weighted average grant  
 date fair value of $0.99 per share;                                                                                            |
| ● | 5,155,060                                                                                                                      
 shares of Common Stock issuable upon the exercise of outstanding warrants as of March 18, 2025, having a weighted average      
 exercise price of $2.51 per share; and                                                                                         |
| ● | 223,522                                                                                                                        
 shares of Common Stock reserved for future issuance pursuant to our existing stock incentive plan.                             |

Except as otherwise noted, the above information reflects and assumes no sale of pre-funded warrants in this offering, which, if sold, would reduce the number of shares of Common Stock that we are offering on a one-for-one basis, no exercise of any common warrants issued in this offering, and no exercise of outstanding stock options or warrants after March 18, 2025.

| 5 |

| CONFIDENTIAL TREATMENT REQUESTED BY IMUNON, INC.PURSUANT TO 17 C.F.R. SECTION 200.83 |

<div align='center'>RISK FACTORS</div>

In evaluating the Company, its business and any investment in the Company, you should carefully consider the following information about risks, together with the other information described in or incorporated by reference in this prospectus, before making an investment in our securities, including the additional risk factors incorporated by reference from Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on February 27, 2025, any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, and all other documents incorporated by reference into this prospectus (see “Incorporation of Certain Information by Reference”). If any of the circumstances or events described below actually